Koers Oxygen Biotherapeutics, Inc. Nasdaq
Aandelen
US69207P2092
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 6,05 mln. 5,64 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -19 mln. -17,69 mln. | Nettowinst (verlies) 2025 * | -18 mln. -16,76 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,38
x | K/w-verhouding 2025 * |
-0,83
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,65% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 50 | 14-07-21 | |
Director of Finance/CFO | 69 | 11/01 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 15-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 04-04-14 |
June Almenoff
BRD | Director/Board Member | 67 | 25-02-21 |
Declan Doogan
BRD | Director/Board Member | 72 | 25-02-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+34,01% | 51,07 mld. | |
-8,02% | 38,78 mld. | |
+34,92% | 38,86 mld. | |
-11,12% | 26,69 mld. | |
+12,56% | 26,35 mld. | |
-19,62% | 19,46 mld. | |
+39,18% | 13,58 mld. | |
+31,47% | 12,46 mld. | |
-3,40% | 11,75 mld. |
- Beurs
- Aandelen
- Koers TENX
- Koers